Cutaneous efficacy and glucocorticoid-sparing effects of anifrolumab in systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Immunol) - Oct 16, 2026 - "DerSimonian-Laird point estimates for secondary efficacy outcomes generally favored anifrolumab, but the HKSJ sensitivity analyses for heterogeneous outcomes and the limited safety data warrant cautious interpretation. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261367219."
Clinical • Journal • Retrospective data • Review • Herpes Zoster • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • Varicella Zoster
|
|
Feiyin Liu; Jianing Wang; Min Liu; Qianwen Lou; Yinan Yang
|